Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideki Enokida

Showing results (141-150 of 177) with videos related to

Pageof 18
Sort By:
International Journal of Molecular Sciences|February 26, 2025
Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell CarcinomaSaeki Saito, Hirofumi Yoshino, Seiya Yokoyama, et al.
International Journal of Clinical Oncology|November 16, 2019
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trialHiroyuki Nishiyama, Yoshiaki Yamamoto, Naoto Sassa, et al.
International Journal of Molecular Sciences|June 19, 2024
LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder CancerJunya Arima, Hirofumi Yoshino, Wataru Fukumoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancerTatsuya Ogishima, Hiroaki Shiina, Julia E Breault, et al.
Plos One|April 5, 2013
Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancerTakeshi Chiyomaru, Soichiro Yamamura, Shinichiro Fukuhara, et al.
Anticancer Research|May 31, 2022
Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysisTaiki Kamijima, Hiroshi Yaegashi, Atsushi Mizokami, et al.
BMC Nephrology|April 8, 2024
Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a retrospective studyTakashi Sakaguchi, Akihiko Mitsuke, Yoichi Osako, et al.
BJUI Compass|February 19, 2024
Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelinesMakito Miyake, Hiroshi Kitamura, Nobutaka Nishimura, et al.
Oncogene|July 12, 2005
Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancerTatsuya Ogishima, Hiroaki Shiina, Julia E Breault, et al.
Cancer Research|March 23, 2005
Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancerHiroaki Shiina, Julia E Breault, William W Basset, et al.
Pageof 18

Showing results (141-150 of 177) with videos related to

Sort By:
Pageof 18
International Journal of Molecular Sciences|February 26, 2025
Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell CarcinomaSaeki Saito, Hirofumi Yoshino, Seiya Yokoyama, et al.
International Journal of Clinical Oncology|November 16, 2019
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trialHiroyuki Nishiyama, Yoshiaki Yamamoto, Naoto Sassa, et al.
International Journal of Molecular Sciences|June 19, 2024
LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder CancerJunya Arima, Hirofumi Yoshino, Wataru Fukumoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancerTatsuya Ogishima, Hiroaki Shiina, Julia E Breault, et al.
Plos One|April 5, 2013
Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancerTakeshi Chiyomaru, Soichiro Yamamura, Shinichiro Fukuhara, et al.
Anticancer Research|May 31, 2022
Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysisTaiki Kamijima, Hiroshi Yaegashi, Atsushi Mizokami, et al.
BMC Nephrology|April 8, 2024
Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a retrospective studyTakashi Sakaguchi, Akihiko Mitsuke, Yoichi Osako, et al.
BJUI Compass|February 19, 2024
Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelinesMakito Miyake, Hiroshi Kitamura, Nobutaka Nishimura, et al.
Oncogene|July 12, 2005
Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancerTatsuya Ogishima, Hiroaki Shiina, Julia E Breault, et al.
Cancer Research|March 23, 2005
Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancerHiroaki Shiina, Julia E Breault, William W Basset, et al.
Pageof 18